RxDoctor Payments Data

Jenny Lee, MD

Internal Medicine · Chicago, ILNPI 1093759490

Payments from drug & device makers

$80,962in general payments, 2019–2025

Across 12 payments — averaging $6746.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$80K
  • Gilead$359
  • AbbVie$74
  • Viiv Healthcare Company$69
  • E.r. Squibb & Sons, L.L.C.$32
  • Organon$16
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,962 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$88,146
Medicare patients
175
Services billed
1,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala186$838,333
DovatoDolutegravir Sodium/Lamivudine138$452,869
JulucaDolutegravir/Rilpivirine76$285,548
TivicayDolutegravir Sodium89$234,960
DescovyEmtricitabine/Tenofov Alafenam77$204,005
PifeltroDoravirine65$123,273
PrezcobixDarunavir/Cobicistat33$102,215
Egrifta SvTesamorelin Acetate11$83,655
CabenuvaCabotegravir/Rilpivirine11$70,244
OzempicSemaglutide61$63,021
MounjaroTirzepatide43$58,891
JardianceEmpagliflozin53$49,366
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$43,743
TrulicityDulaglutide18$25,558
EliquisApixaban19$25,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Tivicay, Cabenuva$69$1,043,621314 claims
GileadBiktarvy, Descovy$359$1,042,339263 claims
Johnson & JohnsonPrezcobix, Xarelto$12$126,61347 claims
PfizerEliquis$15$25,26419 claims
AbbVieSynthroid$74$1,21516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →